Related references
Note: Only part of the references are listed.Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
J. Remon et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer
Jinshuo Fan et al.
GENOMICS (2020)
Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer
Rohan Gupta et al.
ONCOLOGIST (2020)
From patent to patient: analysing access to innovative cancer drugs
Eva Sharpe et al.
DRUG DISCOVERY TODAY (2020)
The biology, function, and biomedical applications of exosomes
Raghu Kalluri et al.
SCIENCE (2020)
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
Diego de Miguel Perez et al.
SCIENTIFIC REPORTS (2020)
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors
Christopher G. Smith et al.
GENOME MEDICINE (2020)
Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
Sonia Gioffre et al.
JOURNAL OF CLINICAL MEDICINE (2020)
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer
Susanne Hipp et al.
CLINICAL CANCER RESEARCH (2020)
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton et al.
NATURE (2020)
Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging
Linda G. Rikkert et al.
PLOS ONE (2020)
Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
Tomoki Kohno et al.
ONCOLOGY LETTERS (2020)
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C Turner et al.
LANCET ONCOLOGY (2020)
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin
Ryan Woodhouse et al.
PLOS ONE (2020)
Development of a serum miRNA panel for detection of early stage non-small cell lung cancer
Lisha Ying et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
Discovery of genomic correlates and tumor purity as an independent clinical factor of poor outcome in advanced prostate cancer lpWGS CNA data
George Seed et al.
CANCER RESEARCH (2020)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
Alexandra M. Miller et al.
NATURE (2019)
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Loredana Puca et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis
Gabriele De Rubis et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer
Natasha B. Leighl et al.
CLINICAL CANCER RESEARCH (2019)
Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer
Susan Slovin et al.
CLINICAL CANCER RESEARCH (2019)
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
Adam Sharp et al.
EUROPEAN UROLOGY (2019)
Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.
Semini Sumanasuriya et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Technologies for circulating tumor cell separation from whole blood
Petra Banko et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Dominic G. Rothwell et al.
NATURE MEDICINE (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement
Laura A. Levit et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Circulating biomarkers for early detection and clinical management of colorectal cancer
Maria Marcuello et al.
MOLECULAR ASPECTS OF MEDICINE (2019)
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Melanie Janning et al.
CANCERS (2019)
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer
Emma Pailler et al.
CLINICAL CANCER RESEARCH (2019)
Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma
Jue-hui Li et al.
MOLECULAR AND CELLULAR PROBES (2019)
307PDEmergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial
F-C Bidard et al.
ANNALS OF ONCOLOGY (2019)
LBA83Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
M Socinski et al.
ANNALS OF ONCOLOGY (2019)
LBA81_PRPhase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
S M Gadgeel et al.
ANNALS OF ONCOLOGY (2019)
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort
Xiaoji Chen et al.
CLINICAL CANCER RESEARCH (2019)
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
Circulating Tumor Cells: Come Together, Right Now, Over Metastasis
Paulo Rodrigues et al.
CANCER DISCOVERY (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal et al.
JAMA ONCOLOGY (2019)
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy
Gerald Li et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping
Stamatia Rontogianni et al.
COMMUNICATIONS BIOLOGY (2019)
Circulating Tumor Cells Strategies for Capture, Analyses, and Propagation
Ashutosh Agarwal et al.
CANCER JOURNAL (2018)
The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review
Pramit Khetrapal et al.
CANCER TREATMENT REVIEWS (2018)
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu et al.
CELL (2018)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
Niven Mehra et al.
EUROPEAN UROLOGY (2018)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials
Glenn Heller et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
Travis A. Clark et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Ben O'Leary et al.
NATURE COMMUNICATIONS (2018)
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
Francesco Sclafani et al.
SCIENTIFIC REPORTS (2018)
Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer The Devil Is in the Detail
Stephen R. Plymate et al.
JAMA ONCOLOGY (2018)
How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring
Leonie L. Zeune et al.
CYTOMETRY PART A (2018)
Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
Khurum H. Khan et al.
CANCER DISCOVERY (2018)
Highly efficient capture of cancer cells expressing EGFR by microfluidic methods based on antigen-antibody association
Takashi Ohnaga et al.
SCIENTIFIC REPORTS (2018)
Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Charles E. Gast et al.
SCIENCE ADVANCES (2018)
Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction
Emmanuel Gabriel et al.
FRONTIERS IN ONCOLOGY (2018)
The RareCyte® platform for next-generation analysis of circulating tumor cells
Eric P. Kaldjian et al.
CYTOMETRY PART A (2018)
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Markus Mayrhofer et al.
GENOME MEDICINE (2018)
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Maryou B. Lambros et al.
CLINICAL CANCER RESEARCH (2018)
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer
C. Fribbens et al.
ANNALS OF ONCOLOGY (2018)
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R. Condorelli et al.
ANNALS OF ONCOLOGY (2018)
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study
Christophe Massard et al.
EUROPEAN JOURNAL OF CANCER (2017)
A conduit to metastasis: circulating tumor cell biology
Douglas S. Micalizzi et al.
GENES & DEVELOPMENT (2017)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Burdensome Research Procedures in Trials: Why Less Is More
Jonathan Kimmelman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients
L. Sorber et al.
LUNG CANCER (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Analysis of DNA methylation in single circulating tumor cells
C. F. Pixberg et al.
ONCOGENE (2017)
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study
Raquel Perez-Lopez et al.
RADIOLOGY (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Burdensome Research Procedures in Trials: Why Less Is More
Jonathan Kimmelman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
Howard I. Scher et al.
CANCER RESEARCH (2017)
Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146
Maria Cristina Rapanotti et al.
CELL DEATH DISCOVERY (2017)
Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.
Kenneth Stephen Thress et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lessons Learned: Transfer of the High-Definition Circulating Tumor Cell Assay Platform to Development as a Commercialized Clinical Assay Platform
P. Kuhn et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Wolfgang J. Janni et al.
CLINICAL CANCER RESEARCH (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Circulating tumor cell technologies
Meghaan M. Ferreira et al.
MOLECULAR ONCOLOGY (2016)
Critical parameters in targeted drug development: the pharmacological audit trail
Udai Banerji et al.
SEMINARS IN ONCOLOGY (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Catherine Alix-Panabieres et al.
CANCER DISCOVERY (2016)
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
Elizabeth A. Punnoose et al.
BRITISH JOURNAL OF CANCER (2015)
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics
Myron G. Best et al.
CANCER CELL (2015)
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
Roberta Ferraldeschi et al.
EUROPEAN UROLOGY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Predicting Radiotherapy Responses and Treatment outcomes Through Analysis of Circulating Tumor DNA
Aadel A. Chaudhuri et al.
SEMINARS IN RADIATION ONCOLOGY (2015)
Epithelial cell adhesion molecule is expressed in a subset of sarcomas and correlates to the degree of cytological atypia in leiomyosarcomas
Kristi Ward et al.
MOLECULAR AND CLINICAL ONCOLOGY (2015)
Circulating Tumor Cells: A Multifunctional Biomarker
Timothy A. Yap et al.
CLINICAL CANCER RESEARCH (2014)
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Jeffrey B. Smerage et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Brigitte Rack et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients
Audrey Vallee et al.
LUNG CANCER (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Circulating Tumor Cells: Application as a Biomarker for Molecular Characterization and Predictor of Survival in an All-Comer Solid Tumor Phase I Clinical Study
Haifeng Bao et al.
PLOS ONE (2013)
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety
C. A. Gomez-Roca et al.
ANNALS OF ONCOLOGY (2012)
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
David Olmos et al.
LANCET ONCOLOGY (2012)
Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers
Geraldine Perkins et al.
PLOS ONE (2012)
Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy
Alejandra Garcia-Villa et al.
FRONTIERS IN ONCOLOGY (2012)
Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials
Lot A. Devriese et al.
CANCER TREATMENT REVIEWS (2011)
Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials
David Olmos et al.
CLINICAL CANCER RESEARCH (2011)
The ethical use of mandatory research biopsies
Erin M. Olson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience
Hazem El-Osta et al.
ONCOLOGIST (2011)
Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival
Sjoerd T. Ligthart et al.
PLOS ONE (2011)
Forty Years of Translational Cancer Research
William N. Hait
CANCER DISCOVERY (2011)
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Craig P. Carden et al.
DRUG DISCOVERY TODAY (2010)
First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity
T. A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients withMetastaticBreast Colorectal and Prostate Cancer
M. Craig Miller et al.
JOURNAL OF ONCOLOGY (2010)
Envisioning the future of early anticancer drug development
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2010)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
CANCER RESEARCH (2009)
From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs
C. P. Carden et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development
Chris H. Takimoto
EUROPEAN JOURNAL OF CANCER (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Steven J. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Sunitha Nagrath et al.
NATURE (2007)
Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer
G. Thomas Budd et al.
CLINICAL CANCER RESEARCH (2006)
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
Daniel F. Hayes et al.
CLINICAL CANCER RESEARCH (2006)
HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients
P Wülfing et al.
CLINICAL CANCER RESEARCH (2006)
Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
U Banerji et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development
P Workman
CURRENT PHARMACEUTICAL DESIGN (2003)
Share Paper
